Amyotrophic Lateral Sclerosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Amylyx, Annexon, Ashvattha, Biogen

September 26 22:46 2023
Amyotrophic Lateral Sclerosis Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | AbbVie, Amylyx, Annexon, Ashvattha, Biogen
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 90+ key pharma and biotech companies are working on 100+ pipeline drugs in the Amyotrophic Lateral Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Amyotrophic Lateral Sclerosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Market. 

The Amyotrophic Lateral Sclerosis Pipeline report embraces in-depth commercial, regulatory, and Amyotrophic Lateral Sclerosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Amyotrophic Lateral Sclerosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Amyotrophic Lateral Sclerosis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Amyotrophic Lateral Sclerosis treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Amyotrophic Lateral Sclerosis therapies segmented into early-stage, mid-stage, and late-stage clinical development.

  • It outlines the major Amyotrophic Lateral Sclerosis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Amyotrophic Lateral Sclerosis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Amyotrophic Lateral Sclerosis therapeutic market.

Amyotrophic Lateral Sclerosis Therapeutics Landscape

Currently, there is no cure for ALS and no effective treatment to halt, or reverse, the progression of the disease. The treatment landscape of ALS includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpool therapy, and others. 

Moreover, there are five drugs approved by the US FDA to treat ALS, namely RELYVRIO, Riluzole, NUEDEXTA, RADICAVA (IV and oral), and TIGLUTIK. Medications are also prescribed to help manage symptoms of ALS, including pain, muscle cramps, stiffness, excess saliva, and phlegm, and the pseudobulbar effect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs are also available to help individuals with pain, depression, sleep disturbances, and constipation. 

To further improve the treatment outlook, about 90+ key companies are developing therapies for Amyotrophic Lateral Sclerosis. ALS pipeline possesses potential drugs in mid and late-stage developments to be launched shortly. The major key players include Tofersen/BIIB067 (Biogen/Ionis Pharmaceuticals), Masitinib (AB Science), NurOwn (Brainstorm-Cell Therapeutics), Gold Nanocrystals/CNM-Au8 (Clene Nanomedicine), Verdiperstat (Biohaven Pharmaceuticals), and others. Currently, Biogen is leading the therapeutics market with its Amyotrophic Lateral Sclerosis drug candidates in the most advanced stage of clinical development. The launch of new therapies may increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of ALS.

Amyotrophic Lateral Sclerosis Companies Actively Working in the Therapeutic Market Include:

AB Science, AbbVie, AI Therapeutics, Inc., AL-S Pharma, Alector Inc., Amylyx Pharmaceuticals, Annexon, Inc., Apellis Pharmaceuticals, Inc., Aquestive Therapeutics, Ashvattha Therapeutics, Inc., Avanir Pharmaceuticals (a subsidiary of Otsuka America), Biogen, Biohaven Pharmaceuticals, Brainstorm Cell Therapeutics, Calico Life Sciences LLC, Cellenkos, Clene Nanomedicine Biosciences, Corcept Therapeutics, Covis, Cytokinetics/Astellas Pharma, Denali Therapeutics Inc., DS Pharma/PTC Therapeutics, Eledon Pharmaceuticals, Ferrer Internacional S.A., Genuv Inc., Helixmith Co., Ltd., InFlectis BioScience, Ionis Pharmaceuticals, Kadimastem, Knopp Biosciences, MediciNova, Mitsubishi Tanabe Pharma Corporation, Molecular Partners, NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Prilenia Therapeutics, Procypra Therapeutics, QurAlis Corporation, Rapa Therapeutics LLC, Retrotope, Inc., Revalesio Corporation, Sanofi, PTC Therapeutics, Seelos Therapeutics, UCB Pharma/Ra Pharmaceuticals, Woolsey Pharmaceuticals, ZZ Biotech, LLC, and others.

Emerging and Marketed Amyotrophic Lateral Sclerosis Drugs Covered in the Report Include:

AIT-101 (LAM-002A) – AI Therapeutics, AMX0035: Amylyx Pharmaceuticals, ANX005: Annexon, , Exservan: Aquestive Therapeutics, ION363: Ionis Pharmaceuticals, Masitinib: AB Sciences, Nuedexta: Avanir Pharmaceuticals, Pridopidine: Prilenia Therapeutics, Radicava: Mitsubishi Tanabe Pharma Corporation, RELYVRIO (AMX0035): Amylyx Pharmaceuticals, RNS60: Revalesio Corporation, Tiglutik/ Teglutik: ITF Pharma, TIGLUTIK/ TEGLUTIK: ITF Pharma, Tofersen: Biogen/Ionis Pharmaceuticals, Verdiperstat: Biohaven, and many more.

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Amyotrophic Lateral Sclerosis Companies Working in the Market @

Analysis of Emerging Amyotrophic Lateral Sclerosis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular

  • Intraocular

  • Intrathecal

  • Intravenous

  • Ophthalmic

  • Oral

  • Parenteral

  • Subcutaneous

  • Topical

  • Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide

  • Peptide

  • Small molecule

Learn How the Amyotrophic Lateral Sclerosis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Amyotrophic Lateral Sclerosis Treatment Patterns

4. Amyotrophic Lateral Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Amyotrophic Lateral Sclerosis Late Stage Products (Phase-III)

7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)

8. Amyotrophic Lateral Sclerosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Amyotrophic Lateral Sclerosis Discontinued Products

13. Amyotrophic Lateral Sclerosis Product Profiles

14. Major Amyotrophic Lateral Sclerosis Companies in the Market

15. Key Products in the Amyotrophic Lateral Sclerosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Amyotrophic Lateral Sclerosis Unmet Needs

18. Amyotrophic Lateral Sclerosis Future Perspectives

19. Amyotrophic Lateral Sclerosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics @ Healthcare Market Research Services

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States